Process chemists consider a host of factors when designing routes to active pharmaceutical ingredients (API’s) which include: safety, number of steps, availability of starting materials, sustainability, and cost.  While transition metal catalyzed transformations are now routine in the synthesis of API’s, the precious metals required for the catalysts such as palladium, iridium, and rhodium present both near-term and long-term challenges in availability, cost, and sustainability.  To mitigate these challenges, base metal catalysis offers both similar and unique reactivity opportunities compared to precious metals.  Our department has recently begun exploring and utilizing nickel catalysts to replace palladium in many C-B, C-C, and C-X bond forming reactions.  Contrary to palladium however, there is far less known about modes of activation, catalytic intermediates, available oxidation states, and tolerable ligand fields.  Herein, we present our initial studies on nickel precatalyst speciation and reduction as it pertains to nickel-catalyzed borylation of aryl halides.

Studies on nickel precatalyst speciation and reduction relevant to Ni-catalyzed borylation of aryl halides

ACS Spring Meeting 2021

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.